Paper Details

  1. Home
  2. Paper Details

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.

Author: AdamekBrygida, Baka-ĆwierzBarbara, Belica-WdowikTeresa, BerakHanna, Białkowska-WarzechaJolanta, BuczyńskaIwona, CitkoJolanta, Czauż-AndrzejukAgnieszka, DerońZbigniew, DobrackiWitold, DybowskaDorota, FlisiakRobert, GarlickiAleksander, GietkaAndrzej, HalotaWaldemar, HorbanAndrzej, JanczewskaEwa, JaroszewiczJerzy, LauransŁukasz, LorencBeata, MazurWłodzimierz, PiekarskaAnna, SimonKrzysztof, SitkoMarek, SochaŁukasz, TomasiewiczKrzysztof, TroninaOlga, Tudrujek-ZdunekMagdalena, Wawrzynowicz-SyczewskaMarta, Zarębska-MichalukDorota

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study compared the efficacy and safety of paritaprevir/ritonavir/ombitasvir+dasasbuvir±ribavirin (PrODR) and ledipasvir/sofosbuvir±RBV (LSR) in patients with hepatitis C virus infection who had failed prior interferon-based triple therapy with protease inhibitors (PI). Both regimens were effective in achieving a sustained virologic response (SVR), but PrODR was associated with a higher rate of adverse events.
Paper Details　
Original Abstract of the Article :
According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior interferon-based triple therapy with protease inhibitors (PI), is a combination of sofosbuvir and NS5A inhibitors. Polish national recommendations al...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240185/

データ提供：米国国立医学図書館（NLM）

Paritaprevir/Ritonavir/Ombitasvir+Dasabuvir vs. Ledipasvir/Sofosbuvir for Hepatitis C

Hepatitis C, a viral infection affecting the liver, requires effective treatment to prevent complications. This study compares the efficacy and safety of two antiviral regimens, paritaprevir/ritonavir/ombitasvir+dasabuvir (PrODR) and ledipasvir/sofosbuvir (LSR), in patients with hepatitis C who had previously failed treatment with interferon-based therapy. The study found that both regimens demonstrated comparable efficacy in achieving sustained virologic response (SVR), suggesting multiple effective treatment options for this challenging patient population.

Effective Treatment Options for Hepatitis C: A Tale of Two Regimens

This study offers valuable information for clinicians treating patients with hepatitis C who have previously failed interferon-based therapy. The findings indicate that both PrODR and LSR are effective treatment options, providing clinicians with flexibility in choosing the best regimen based on individual patient factors.

Navigating the Desert of Hepatitis C Treatment

Imagine a traveler navigating a vast and unforgiving desert, seeking a path to recovery from a debilitating illness. Similarly, individuals with hepatitis C often face a challenging journey in finding effective treatment that eradicates the virus and restores their health. This study offers two promising oases, PrODR and LSR, providing clinicians with valuable tools to guide patients towards a healthier future.

Dr. Camel's Conclusion

This study highlights the progress made in hepatitis C treatment, offering two effective antiviral regimens for patients who have previously failed therapy. As we continue to explore the desert of knowledge in search of better treatments, we remain optimistic about the potential to conquer hepatitis C and improve the lives of those affected by this debilitating disease.
Date :
  1. Date Completed 2019-01-11
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30445916

DOI: Digital Object Identifier

PMC6240185

Related Literature

Article Analysis
・Effects of telaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.